Something Everybody Are Trying To Learn Concerning Fludarabine

REEVES*, P. BOWDEN? and A. COSTELLO*, *The Royal Melbourne Hospital, Melbourne, Australia; ?Epworth Healthcare, Richmond, Australia Introduction:?Metastatic prostate cancer has been traditionally treated with androgen deprivation therapy (ADT). ADT is however associated with debilitating side effects. Oligometastatic disease may represent https://en.wikipedia.org/wiki/Chlormezanone an intermediate disease stage that is amenable to aggressive local therapy, allowing deferral of ADT commencement. Stereotactic body radiotherapy (SBRT) is relatively non-invasive treatment that delivers an ablative dose of radiotherapy to target tissues, while minimising scatter to adjacent structures. Early evidence in other cancers suggests SBRT is a safe and effective treatment for oligometastatic disease, which may even offer cure in selected patients. The objective of this study is to establish the effectiveness and safety of SBRT in treating oligometastatic prostate cancer. Methods:?We performed a retrospective analysis of all men with oligometastatic prostate cancer (defined as 5 or less sites of metastasis) treated with SBRT. Effectiveness of treatment was measured by PSA serum levels and ADT use. Results:?Between 2007 and 2013, 29 SBRT treatments were performed in 27 patients http://www.selleckchem.com/products/Nolvadex.html with oligometastatic prostate cancer. Median follow-up duration was 5 months (range 6 weeks to 4.3 years). Pre-treatment characteristics: Median age was 70 (range 50�C80). 45% of patients were hormone na?ve, 25% were castrate resistant and 30% had received ADT at some time but were not castrate resistant. http://www.selleckchem.com/products/Fludarabine(Fludara).html Oligometastases were treated between 2 months to 13 years (median 4?yr) after radical treatment of the primary tumour. PSA levels prior to SBRT were